Steminent Biotherapeutics Inc. (TPEX:7729)

Steminent Biotherapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	891.65	499.18	205.4	451.86	153.43	230.56
Short-Term Investments	-	-	11.6	-	-	-
Cash & Short-Term Investments	891.65	499.18	217	451.86	153.43	230.56
Cash Growth	442.12%	130.03%	-51.98%	194.50%	-33.45%	464.90%
Other Receivables	1.24	0.73	0.94	0.84	0.33	0.78
Receivables	1.24	0.73	0.94	0.84	0.33	0.78
Inventory	15.86	15.06	12	7.67	3.48	10.4
Prepaid Expenses	25.21	2.89	5.82	-	-	1.14
Other Current Assets	-	-	-	6.09	3.91	-
Total Current Assets	933.96	517.86	235.76	466.46	161.15	242.88
Property, Plant & Equipment	134.54	149.35	168.18	83.16	58.87	22.8
Other Intangible Assets	1.48	1.78	2.39	0.51	0.32	0.16
Other Long-Term Assets	32.38	29.51	30.34	43.74	15.31	13.66
Total Assets	1,102	698.49	436.66	593.88	235.65	279.5

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.29	2.85	2.54	2.15	1.93	0.65
Accrued Expenses	11.92	11.58	11.41	13.81	10.11	10.01
Current Portion of Leases	14.57	14.2	13.68	13.15	7.17	7.9
Current Unearned Revenue	-	-	-	-	0.46	1.09
Other Current Liabilities	9.03	9.52	4.09	9.55	4.46	2.85
Total Current Liabilities	42.74	38.15	31.73	38.66	24.12	22.5
Long-Term Debt	19.19	21.67	-	-	-	-
Long-Term Leases	30.93	37.5	50.09	62.23	48	11.27
Long-Term Deferred Tax Liabilities	0.03	0.03	0.15	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	1.46
Total Liabilities	92.89	97.34	81.97	100.89	72.11	35.23

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	805.79	666.34	560.45	557.95	444.94	444.94
Additional Paid-In Capital	1,273	710.51	581.43	580.17	239.16	239.16
Retained Earnings	-1,099	-988.31	-814.27	-655.53	-526.3	-440.82
Comprehensive Income & Other	30.27	212.61	27.09	10.39	5.74	0.99
Shareholders' Equity	1,009	601.15	354.7	492.99	163.54	244.27
Total Liabilities & Equity	1,102	698.49	436.66	593.88	235.65	279.5

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	69.61	73.36	63.78	75.38	55.16	19.17
Net Cash (Debt)	822.03	425.81	153.23	376.48	98.27	211.39
Net Cash Growth	915.16%	177.90%	-59.30%	283.12%	-53.51%	-
Net Cash Per Share	12.14	7.22	2.74	7.77	2.21	6.00
Filing Date Shares Outstanding	80.58	66.63	56.05	55.8	44.49	44.49
Total Common Shares Outstanding	80.58	66.63	56.05	55.8	44.49	44.49
Working Capital	891.22	479.71	204.03	427.8	137.03	220.38
Book Value Per Share	12.53	9.02	6.33	8.84	3.68	5.49
Tangible Book Value	1,008	599.37	352.31	492.47	163.22	244.11
Tangible Book Value Per Share	12.51	9.00	6.29	8.83	3.67	5.49
Machinery	105.43	109.69	99.07	42.81	34.07	32.36
Leasehold Improvements	79.08	79.08	79.08	41.5	41.05	40.82

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 6, 2026

Data Sources Report a data error